Beike Biopharma initiates Phase I clinical trial of HSV-2 mRNA vaccine
September 10, 2025
Source: drugdu
94
According to People's Finance News on September 9, " Bai Ke BioAccording to a WeChat official account, on September 9th, Beike Bio successfully held a kickoff meeting for the "Phase I Dose-Escalation Trial of the Safety, Tolerability, and Immunogenicity of an HSV-2 mRNA Vaccine in Subjects Aged 18 to 55 with Different Serological Infections" at Beijing Jishuitan Hospital. The kickoff meeting provided systematic training and work deployment on core topics such as genital herpes disease and vaccine development background, GCP standards, clinical trial protocols, investigator brochures, sample management, and on-site procedures. Subsequently, all work preparations were in place, and subject enrollment was about to begin in full swing.
Source：https://finance.eastmoney.com/a/202509093508939621.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
